Tagged with P

Adimmune Corporation The president of Adimmune Corporation discusses how the avian flu outbreak of 2006/2007 changed the course of the drug manufacturing industry in Taiwan, what that meant for Adimmune, and how he plans to get Adimmune and the Taiwanese biotech industry on the map. Over the past few decades, how has…

Life Sciences The funding of Canada’s biotech industry has changed drastically in recent years. Peter Van Der Velden of Lumira Capital discusses those changes and how his venture capital business is adapting to this evolving environment. Lumira has been involved with numerous acquisitions over the years. Could you highlight a couple of…

R&D Tony Cruz of Transition Therapeutics discusses the challenges of biotech companies in Canada and his company’s unique business model that has adapted to the changing needs of big pharma through risk mitigation. You founded Transition Therapeutics in 1998. What was the reasoning behind founding a biotech company focused on CNS…

Biosimilars Dr. Liu, President and CEO of EirGenix, talks about why he sees Taiwan as the ideal market for a CDMO like Eirgenix, why he believes that despite the skepticism, biosimilars will be able to overcome the initial barriers, and where he sees EiGenix in the next several years. What has…

R&D Whaijen Soo, Managing Director of Supra Integration and Incubation Center (Si2C) speaks about Taiwan’s biotech industry, emphasizing the need for risk tolerance and understanding investing rationale in propelling Taiwan’s industry to the global forefront.  Taiwan Supra Integration and Incubation Center (Si2C), was launched in November 2011 with the intention of…

Biosimilars Audrey Tseng, Deputy Chairman of PwC Taiwan with PwC Partners Lily Wong and Andy Chang, delve into factors behind the booming pharma and biotech industry in Taiwan, how to prevent a bubble burst, and the crucial next steps in maintaining the momentum to continue growth within the industry. Please start…

Chang Gung Memorial Hospital Dr Yu-Ray Chen, Professor of Surgery at Chang Gung Memorial Hospital discusses the current state of Taiwan’s healthcare system, highlighting the fact that its current condition is unsustainable in the long run, and emphasizes the importance of international growth and collaboration for CGMH over the next five years.  Chang Gung…

diabetes Christine Marie D. Rosal, Country Manager of Novo Nordisk Pharmaceuticals (Philippines) gives a startling image of the current state of diabetes in the Philippines, the major reasons behind the soaring rates of diabetes and what the government along with companies such as Novo Nordisk can do to prevent a worsening…

Generics Executive Director, Teodoro B. Padilla, and Reiner W. Gloor, Adviser of Pharmaceutical & Healthcare Association of the Philippines (PHAP) argue that certain government initiatives, like discounted prices for senior citizens and students without financing them, put a perilous amount of pressure on the sector, and the necessity of raising awareness…

UAE The two founders and managing partners of Genpharm talk about the market dynamics of the UAE, and the gaps in the market that the company was able to fill with its portfolio offering.    Karim, can you speak to us about the birth of Genpharm, and more broadly about your…

Basic Research “If you look at the cuts in the public sector, the science budget has been relatively lightly touched. This sends a signal at a very high level that science, the knowledge economy, and the smart training of people are very important for our economic recovery,” says Mark Ferguson, Director General,…

Life Sciences Michael Chiang, the Executive President of Panion & BF Biotech speaks about the incredible growth of the company over the past year, what has contributed to this success and where Panion & BF will be in the next five years. Please provide us with a brief insight into the history…